（编辑 姚尧） 证券日报网讯 7月29日晚间，昭衍新药发布公告称，公司股票于2025年7月25日、7月28日和7月29日连 续3个交易日内日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情形。经公司自查并书面 征询公司控股股东及实际控制人，截至本公告披露日，公司及公司控股股东、实际控制人确认不存在应 披露而未披露的重大信息。 ...

Core Viewpoint - The company Zhaoyan New Drug (603127) has experienced a significant stock price fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days [1] Summary by Relevant Sections - **Stock Price Movement** - The company's A-share stock saw a price increase exceeding 20% over three trading days on July 25, 28, and 29, 2025, indicating unusual trading activity [1] - **Regulatory Compliance** - The stock price movement falls under the category of abnormal trading fluctuations as per the Shanghai Stock Exchange trading rules [1] - **Company's Disclosure** - Following a self-examination and inquiry with the controlling shareholder and actual controller, the company confirmed that there are no undisclosed significant information as of the date of the announcement [1]

经公司自查并书面征询公司控股股东及实际控制人，截至本公告披露日，公司及公司控股股东、实际控 制人确认不存在应披露而未披露的重大信息。 昭衍新药(06127)公布，公司A股股票于 2025 年 7 月 25 日、7 月 28 日和 7 月 29 日连续 3 个交易日内日 收盘价格涨幅偏离值累计超过 20%。根据《上海证券交易所交易规则》的有关规定，属于股票交易异 常波动情形。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：603127 证券简称：昭衍新药 公告编号：2025-028 股票交易异常波动公告 北京昭衍新药研究中心股份有限公司 经公司自查，并书面征询控股股东及实际控制人，截至本公告披露日，不存 在影响公司股票交易价格异常波动的重大事项，不存在涉及公司应披露而未披露 的重大信息，包括但不限于重大资产重组、发行股份、上市公司收购、债务重组、 资产剥离和资产注入等重大事项。 针对公司股票交易异常波动，公司对有关事项进行了核查，现将有关情况说 明如下： 北京昭衍新药研究中心股份有限公司（以下简称"公司"）股票于2025 年7月25日、7月28日和7月29日连续3个交易日内日收盘价格涨幅偏离值 累计超过20%。根据《上海证券交易所交易规则》的有关规定，属于股 票交易异常波动情形。 经公司自查并书面征询公司控股股东及实际控制人，截至本公告披露日， 公司及公司控股股东、实际控制人确认不存在应披露而未披露的重大信 息。 （一）生产经营情况 经自查，公司目前生产经营活动正常 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年7月29日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 先 生、陽 ...

经济观察网 昭衍新药（603127）公告，公司股票于2025年7月25日、7月28日和7月29日连续3个交易日 内日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情形。经公司自查并书面征询公司控股 股东及实际控制人，确认不存在应披露而未披露的重大信息。公司生产经营活动正常，内、外部经营环 境未发生重大变化，不存在影响公司股票交易价格异常波动的应披露而未披露的重大信息。 ...

Group 1 - The Hong Kong pharmaceutical outsourcing sector has strengthened, with companies such as Kanglong Chemical (03759.HK) and WuXi AppTec (02359.HK) rising over 3% [1] - Other companies like Zhaoyan New Drug (06127.HK) and Tiger Med (03347.HK) also experienced gains [1]

Company Overview - Zhao Yan New Drug closed at 32.0 yuan, up 7.02%, with a rolling PE ratio of 61.91, the lowest in 488 days, and a total market value of 23.983 billion yuan [1] - The company specializes in non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1] Financial Performance - For Q1 2025, the company reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit was 41.1195 million yuan, a year-on-year increase of 115.11%, with a gross margin of 28.61% [1] Shareholder Information - As of September 30, 2020, the number of shareholders was 17,882, a decrease of 783 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical services industry is 48.04, with a median of 58.89, placing Zhao Yan New Drug at 30th in the industry ranking [1][2] - The static PE ratio for Zhao Yan New Drug is 32.77, with a price-to-book ratio of 2.96 [2]

Core Viewpoint - The stock of Zhaoyan New Drug closed at 27.33 yuan, up 6.43%, with a rolling PE ratio of 52.87, marking a new low in 405 days, and a total market capitalization of 20.483 billion yuan [1]. Group 1: Company Performance - As of the first quarter of 2025, Zhaoyan New Drug reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit reached 41.12 million yuan, a year-on-year increase of 115.11%, with a gross profit margin of 28.61% [1]. - The company specializes in non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1]. Group 2: Market Position - Zhaoyan New Drug's PE ratio of 52.87 is higher than the industry average of 45.40 and the industry median of 52.21, ranking 30th among its peers [2]. - A total of 17 institutions hold shares in Zhaoyan New Drug, with a combined holding of 10.9687 million shares valued at 231 million yuan [1].

Group 1 - The CXO sector is experiencing a strong rebound, with notable gains in companies such as Zhaoyan New Drug (up over 8%) and Kanglong Chemical (up over 6%) [1][3] - A-share's largest medical ETF (512170) reached a nearly 4-month high, with trading volume exceeding 400 million yuan within the first 30 minutes of trading [1] - Several leading CXO companies have reported positive mid-year earnings forecasts, with Zhaoyan New Drug expecting a net profit increase of up to 144% and WuXi AppTec also projecting over 100% growth [3][4] Group 2 - Institutional interest in the healthcare sector remains high, particularly in pharmaceutical and biotechnology industries, with a focus on CXO services and humanoid robotics [4] - China International Capital Corporation (CICC) highlights the improved financing environment for innovative drugs, positively impacting orders for domestic CROs and upstream research services [5] - CICC recommends focusing on CXO and medical devices, as well as the largest medical ETF (512170) and the first domestic drug ETF (562050), which targets leading pharmaceutical companies [5]